Michael Saribalas
Psychiatry · Columbus, OHNPI 1164454211
Payments from drug & device makers
Across 1,403 payments — averaging $843.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$347K
- AbbVie$307K
- E.r. Squibb & Sons, L.L.C.$193K
- Axsome Therapeutics, Inc.$183K
- Idorsia Pharmaceuticals US Inc$67K
- Otsuka America Pharmaceutical, Inc.$53K
- plus $34K from 8 others
What the payments were for
- Consulting fees$143,29012%
- Speaking & faculty fees$926,49878%
- Travel & lodging$86,9537%
- Food & beverage$26,0332%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 366 | $346,733 |
| AbbVie(2 entities) | 472 | $307,261 |
| E.r. Squibb & Sons, L.L.C. | 195 | $193,041 |
| Axsome Therapeutics, Inc. | 124 | $182,652 |
| Idorsia Pharmaceuticals US Inc | 54 | $66,594 |
| Otsuka America Pharmaceutical, Inc. | 78 | $52,591 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $18,028 |
| Vanda Pharmaceuticals Inc. | 23 | $15,404 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $173 |
| Lundbeck LLC | 16 | $152 |
| Noctrix Health, Inc. | 1 | $151 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,182,828 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 173 | $262,493 |
| AristadaAripiprazole Lauroxil | 56 | $198,275 |
| TrintellixVortioxetine Hydrobromide | 179 | $116,962 |
| AuvelityDextromethorphan Hbr/Bupropion | 90 | $96,486 |
| RexultiBrexpiprazole | 61 | $94,227 |
| FetzimaLevomilnacipran Hcl | 27 | $23,388 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $22,712 |
| Chlorpromazine Hcl | 57 | $17,379 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $15,111 |
| Lurasidone Hcl | 33 | $12,163 |
| Vilazodone Hcl | 104 | $11,715 |
| Tiagabine Hcl | 40 | $8,919 |
| QuviviqDaridorexant Hcl | 18 | $8,865 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 118 | $8,116 |
| JardianceEmpagliflozin | 12 | $7,780 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima, Viibryd | $307,261 | $289,295212 claims |
| Alkermes, Inc.Aristada, Lybalvi | $346,733 | $220,98869 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $18,028 | $132,074215 claims |
| Axsome Therapeutics, Inc.Auvelity | $182,652 | $96,48690 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $52,591 | $94,22761 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $66,594 | $8,86518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Columbus
- Fred RomeoColumbus$2.3M
- Kevin WareColumbus$1.1M
- Kevin ReevesColumbus$286K
- Dallas ErdmannColumbus$125K
- Daniel LeeColumbus$113K
- Peter ZafiridesColumbus$109K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.